Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, UnitedHealth Group, Johnson & Johnson, and AbbVie. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$719.85 -33.86 (-4.49%)
Closing price 03:59 PM Eastern
Extended Trading
$717.25 -2.60 (-0.36%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is $722.03, which may be seen as an attractive entry point for investors looking for potential growth.
  • Eli Lilly and Co has a robust market capitalization of $684.61 billion, indicating a strong position in the pharmaceutical industry and potential for stability.
  • The company has announced a significant share buyback plan of $15.00 billion, suggesting that its leadership believes the stock is undervalued, which can enhance shareholder value.

Cons of Eli Lilly and Company

  • The company recently reported earnings per share (EPS) of $5.32, which missed the consensus estimate of $5.45, raising concerns about its short-term financial performance.
  • With a price-to-earnings (P/E) ratio of 61.66, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
  • The debt-to-equity ratio stands at 2.00, indicating a higher level of debt relative to equity, which can pose risks in times of economic downturns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$682.54 billion
P/E Ratio
61.47
Consensus Rating
Moderate Buy
Consensus Price Target
$1,017.67 (+41.4% Upside)
Volume
4.16 million shares
Average Volume
3.37 million shares
Today's Range
$691.77
$741.95
50-Day Range
$719.85
$930.22
52-Week Range
$677.09
$972.53
Dividend Yield
0.76%
UnitedHealth Group stock logo

2. UnitedHealth Group NYSE:UNH

$595.07 +16.57 (+2.86%)
Closing price 03:59 PM Eastern
Extended Trading
$591.98 -3.09 (-0.52%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • UnitedHealth Group is expected to post earnings per share of 29.54 for the current year, indicating strong profitability and growth potential.
  • The company recently declared a quarterly dividend of $2.10 per share, which translates to an annualized dividend of $8.40 and a yield of 1.60%. This consistent dividend payment can provide a steady income stream for investors.
  • Insider buying activity has been noted, with a director purchasing 1,000 shares at an average cost of $511.57 per share. This suggests confidence in the company's future performance, as insiders typically have a better understanding of the company's prospects.

Cons of UnitedHealth Group

  • Despite the positive outlook, the stock price may be perceived as high, which could deter value-focused investors looking for bargains.
  • Corporate insiders own only 0.33% of the company's stock, which may raise concerns about alignment between management and shareholder interests.
  • The healthcare sector is subject to regulatory changes and uncertainties, which can impact profitability and operational stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$544.32 billion
P/E Ratio
38.39
Consensus Rating
Buy
Consensus Price Target
$630.35 (+5.9% Upside)
Volume
8.64 million shares
Average Volume
4.35 million shares
Today's Range
$580.00
$601.88
50-Day Range
$461.09
$595.07
52-Week Range
$436.38
$630.73
Dividend Yield
1.55%
Johnson & Johnson stock logo

3. Johnson & Johnson NYSE:JNJ

$148.62 -2.35 (-1.56%)
Closing price 03:59 PM Eastern
Extended Trading
$148.97 +0.35 (+0.24%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Strong Financial Performance: Johnson & Johnson reported a quarterly revenue of $22.52 billion, exceeding analyst expectations, which indicates robust demand for its products and effective management.
  • Consistent Earnings Growth: The company achieved earnings per share (EPS) of $2.04, surpassing estimates by $0.05, showcasing its ability to generate profits consistently.
  • Stable Market Position: With a market capitalization of $362.60 billion, Johnson & Johnson is a leading player in the healthcare sector, providing a sense of stability and reliability for investors.

Cons of Johnson & Johnson

  • High Price-to-Earnings Ratio: With a PE ratio of 22.63, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
  • Slower Growth in EPS: The company’s EPS decreased from $2.29 in the same quarter last year to $2.04, indicating a potential slowdown in profit growth, which could raise concerns among investors.
  • Market Volatility: The beta of 0.49 suggests that the stock is less volatile than the market, but it may also indicate limited growth potential, which could be a drawback for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$358.15 billion
P/E Ratio
22.35
Consensus Rating
Moderate Buy
Consensus Price Target
$171.67 (+15.5% Upside)
Volume
13.82 million shares
Average Volume
7.94 million shares
Today's Range
$145.13
$151.20
50-Day Range
$148.62
$167.57
52-Week Range
$140.68
$169.99
Dividend Yield
3.10%
AbbVie stock logo

4. AbbVie NYSE:ABBV

$173.80 -6.04 (-3.36%)
Closing price 03:59 PM Eastern
Extended Trading
$174.20 +0.40 (+0.23%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has received multiple upgrades from analysts, including a "strong-buy" rating, indicating strong confidence in the company's future performance.
  • The stock has a consensus price target of $211.45, suggesting potential for price appreciation from its current trading price of $186.11.
  • Institutional investors own 70.23% of AbbVie, reflecting strong institutional confidence and support for the company's growth prospects.

Cons of AbbVie

  • Insiders have sold a significant number of shares recently, totaling 113,471 shares worth over $23 million, which may raise concerns about their confidence in the company's future performance.
  • The company's high P/E ratio of 77.55 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • AbbVie has a relatively low current ratio of 0.66, indicating potential liquidity issues, as it may not have enough short-term assets to cover its short-term liabilities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$307.44 billion
P/E Ratio
72.42
Consensus Rating
Moderate Buy
Consensus Price Target
$210.71 (+21.2% Upside)
Volume
13.96 million shares
Average Volume
5.93 million shares
Today's Range
$164.97
$178.00
50-Day Range
$173.80
$216.62
52-Week Range
$153.58
$218.66
Dividend Yield
3.25%
Novo Nordisk A/S stock logo

5. Novo Nordisk A/S NYSE:NVO

$61.12 -3.98 (-6.11%)
Closing price 03:59 PM Eastern
Extended Trading
$61.52 +0.40 (+0.65%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Recent earnings results showed a strong performance, with Novo Nordisk reporting $0.91 earnings per share, exceeding analysts' expectations of $0.88. This indicates robust financial health and effective management.
  • The company has a high net margin of 34.81%, suggesting that it retains a significant portion of revenue as profit, which is attractive for investors looking for profitability.
  • As of the latest trading session, Novo Nordisk's stock price is $62.58, which reflects a significant drop from its 52-week high of $148.15. This could present a buying opportunity for investors looking for undervalued stocks.

Cons of Novo Nordisk A/S

  • Shares of Novo Nordisk have recently experienced a decline, trading down 6.7% in one session, which may indicate volatility and potential risks for investors.
  • The company's current ratio is 0.74, which is below 1.0, suggesting that it may not have enough short-term assets to cover its short-term liabilities, raising concerns about liquidity.
  • With a debt-to-equity ratio of 0.62, while not excessively high, it indicates that the company is using some leverage, which can increase financial risk, especially in uncertain market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$274.26 billion
P/E Ratio
18.58
Consensus Rating
Moderate Buy
Consensus Price Target
$145.25 (+137.7% Upside)
Volume
9.97 million shares
Average Volume
5.77 million shares
Today's Range
$59.32
$63.24
50-Day Range
$61.12
$90.94
52-Week Range
$59.37
$148.15
Dividend Yield
2.62%
Remove Ads
Abbott Laboratories stock logo

6. Abbott Laboratories NYSE:ABT

$124.36 -2.68 (-2.11%)
Closing price 03:59 PM Eastern
Extended Trading
$124.50 +0.15 (+0.12%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories has received multiple upgrades from research firms, with price targets now reaching as high as $158.00, indicating strong market confidence in the company's growth potential.
  • The company has a solid payout ratio of 30.85%, suggesting a commitment to returning value to shareholders through dividends while still retaining enough earnings for growth.
  • Recent insider trading shows that a senior vice president recently sold shares but still holds a significant stake, indicating confidence in the company's future performance.

Cons of Abbott Laboratories

  • Despite positive ratings, the stock has seen insider selling, with over 116,000 shares sold in the last 90 days, which could signal a lack of confidence among some insiders.
  • Hedge fund ownership is high at 75.18%, which can lead to volatility if these institutional investors decide to sell off their positions quickly.
  • While the company has a strong product portfolio, it faces intense competition in the healthcare sector, which could impact market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$220.33 billion
P/E Ratio
16.26
Consensus Rating
Moderate Buy
Consensus Price Target
$137.94 (+10.9% Upside)
Volume
11.09 million shares
Average Volume
5.99 million shares
Today's Range
$122.02
$126.82
50-Day Range
$123.63
$140.13
52-Week Range
$99.71
$141.23
Dividend Yield
1.90%
Novartis stock logo

7. Novartis NYSE:NVS

$103.84 -0.01 (-0.01%)
Closing price 03:59 PM Eastern
Extended Trading
$105.76 +1.93 (+1.86%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Recent upgrades from analysts, including a "strong-buy" rating from StockNews.com, indicate growing confidence in Novartis AG's future performance.
  • The stock is currently priced at $105.79, which is below its 12-month high of $120.92, suggesting potential for price appreciation.
  • Institutional interest remains strong, with 13.12% of the stock owned by institutional investors and hedge funds, reflecting confidence in the company's stability and growth prospects.

Cons of Novartis

  • Recent trading activity shows a decline of 5.8%, which may indicate short-term weakness and investor uncertainty about the stock's performance.
  • Analysts have issued three sell ratings and several underweight ratings, suggesting that some experts believe the stock may not perform well in the near term.
  • The company's beta of 0.56 indicates lower volatility compared to the market, which may limit potential gains during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$212.24 billion
P/E Ratio
17.66
Consensus Rating
Reduce
Consensus Price Target
$123.38 (+18.8% Upside)
Volume
4.21 million shares
Average Volume
1.54 million shares
Today's Range
$100.49
$104.34
50-Day Range
$101.80
$115.60
52-Week Range
$92.35
$120.92
Dividend Yield
2.24%
AstraZeneca stock logo

8. AstraZeneca NASDAQ:AZN

$64.87 -1.89 (-2.83%)
Closing price 04:00 PM Eastern
Extended Trading
$65.50 +0.63 (+0.97%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • AstraZeneca has recently received positive ratings from analysts, with UBS Group upgrading the stock from "neutral" to "buy" and Morgan Stanley initiating coverage with an "overweight" rating, indicating strong confidence in the company's future performance.
  • The company has declared a semi-annual dividend of $1.03 per share, which is a significant increase from the previous dividend of $0.49, reflecting a commitment to returning value to shareholders.
  • As of the latest trading session, AstraZeneca's stock price is $68.46, which is positioned well within its 12-month range of $62.75 to $87.68, suggesting potential for price appreciation.

Cons of AstraZeneca

  • The stock has recently experienced a decline of 7.4%, which may indicate volatility and potential challenges in maintaining investor confidence.
  • AstraZeneca reported earnings per share (EPS) of $1.05, which fell short of the consensus estimate of $1.10, suggesting that the company may be facing operational challenges that could impact future profitability.
  • The company's debt-to-equity ratio stands at 0.65, which, while not excessively high, indicates that AstraZeneca has a moderate level of debt that could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$201.18 billion
P/E Ratio
28.70
Consensus Rating
Buy
Consensus Price Target
$89.75 (+38.4% Upside)
Volume
9.76 million shares
Average Volume
5.26 million shares
Today's Range
$63.08
$65.91
50-Day Range
$64.87
$77.96
52-Week Range
$61.24
$87.68
Dividend Yield
3.01%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$77.42 -4.49 (-5.48%)
Closing price 03:59 PM Eastern
Extended Trading
$77.60 +0.18 (+0.23%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck's stock is currently trading at $80.87, which may present a buying opportunity for investors looking for value in a well-established pharmaceutical company.
  • Recent insider buying activity, including a director purchasing shares, indicates confidence in the company's future performance, which can be a positive signal for potential investors.
  • Merck has a strong market capitalization of approximately $198.70 billion, reflecting its stability and ability to invest in research and development for new products.

Cons of Merck & Co., Inc.

  • Merck's stock has recently experienced a decline of 0.4%, which may indicate short-term volatility and uncertainty in the market.
  • Several analysts have downgraded their ratings for Merck, with target prices being reduced, which could reflect concerns about future growth prospects.
  • The company has a relatively low P/E ratio of 11.70, which, while it may suggest value, could also indicate that the market has lower expectations for growth compared to peers.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$195.57 billion
P/E Ratio
11.50
Consensus Rating
Moderate Buy
Consensus Price Target
$115.50 (+49.2% Upside)
Volume
19.30 million shares
Average Volume
11.47 million shares
Today's Range
$75.96
$81.12
50-Day Range
$77.42
$95.13
52-Week Range
$75.99
$134.63
Dividend Yield
3.75%
Intuitive Surgical stock logo

10. Intuitive Surgical NASDAQ:ISRG

$489.52 -33.43 (-6.39%)
Closing price 04:00 PM Eastern
Extended Trading
$486.26 -3.26 (-0.67%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Recent upgrades from multiple analysts, including a price target increase from JPMorgan Chase & Co. to $675.00, indicate strong market confidence in the company's growth potential.
  • The stock currently trades around $566.60, which is positioned favorably given the consensus price target of $611.86, suggesting potential for price appreciation.
  • Intuitive Surgical, Inc. has a robust pipeline of innovative products aimed at enhancing minimally invasive surgical procedures, which could drive future revenue growth.

Cons of Intuitive Surgical

  • Truist Financial recently lowered its target price to $605.00, which may signal concerns about the company's short-term performance.
  • One analyst has rated the stock with a sell rating, indicating that there are differing opinions on the stock's future performance.
  • Insider selling has been significant, with over 33,000 shares sold recently, which could raise concerns about the executives' confidence in the company's future prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$174.36 billion
P/E Ratio
76.37
Consensus Rating
Moderate Buy
Consensus Price Target
$611.86 (+25.0% Upside)
Volume
4.05 million shares
Average Volume
1.59 million shares
Today's Range
$472.02
$510.60
50-Day Range
$451.58
$608.48
52-Week Range
$364.17
$616.00
Dividend Yield
N/A
Remove Ads
Thermo Fisher Scientific stock logo

11. Thermo Fisher Scientific NYSE:TMO

$426.67 -26.88 (-5.93%)
Closing price 03:59 PM Eastern
Extended Trading
$429.50 +2.83 (+0.66%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The stock is currently priced at $437.80, which may present a buying opportunity for investors looking for growth potential.
  • Thermo Fisher Scientific Inc. recently reported earnings per share (EPS) of $6.10, exceeding analysts' expectations, indicating strong financial performance and potential for future growth.
  • The company has a solid market capitalization of $165.16 billion, reflecting its stability and position as a leader in the life sciences sector.

Cons of Thermo Fisher Scientific

  • The stock has experienced a recent decline, with a 7.99% decrease in insider positions, which may signal a lack of confidence among executives.
  • The company has a relatively high price-to-earnings (P/E) ratio of 26.49, which could indicate that the stock is overvalued compared to its earnings.
  • Despite a strong market position, the company faces competition in the life sciences sector, which could impact future growth and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$160.97 billion
P/E Ratio
25.81
Consensus Rating
Moderate Buy
Consensus Price Target
$647.43 (+51.7% Upside)
Volume
3.85 million shares
Average Volume
1.69 million shares
Today's Range
$415.31
$448.60
50-Day Range
$417.57
$581.72
52-Week Range
$409.85
$627.88
Dividend Yield
0.37%
Amgen stock logo

12. Amgen NASDAQ:AMGN

$281.41 -9.68 (-3.33%)
Closing price 04:00 PM Eastern
Extended Trading
$283.40 +1.98 (+0.71%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. has received multiple positive ratings from analysts, including an "outperform" rating with a target price of $324.00, indicating strong potential for price appreciation.
  • The stock is currently trading at approximately $289.69, which is near its 12-month low of $253.30, suggesting a potential buying opportunity for investors looking for value.
  • With a market capitalization of around $155.62 billion, Amgen Inc. is a well-established company, providing stability and confidence for investors.

Cons of Amgen

  • Amgen Inc. has a high debt-to-equity ratio of 9.62, indicating that the company relies heavily on debt financing, which can pose risks, especially in volatile market conditions.
  • Despite positive ratings, two analysts have issued sell ratings, suggesting that there are concerns about the stock's future performance.
  • The company's price-to-earnings (P/E) ratio of 38.37 is relatively high, which may indicate that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$151.17 billion
P/E Ratio
37.27
Consensus Rating
Hold
Consensus Price Target
$315.22 (+12.0% Upside)
Volume
4.68 million shares
Average Volume
2.77 million shares
Today's Range
$269.67
$288.52
50-Day Range
$280.26
$327.36
52-Week Range
$253.30
$346.85
Dividend Yield
3.07%
Boston Scientific stock logo

13. Boston Scientific NYSE:BSX

$92.36 -4.41 (-4.56%)
Closing price 03:59 PM Eastern
Extended Trading
$92.52 +0.16 (+0.18%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • Recent upgrades from multiple analysts, including Deutsche Bank and Raymond James, indicate strong confidence in the stock, with price targets set as high as $122.00, suggesting potential for significant returns.
  • The current stock price is $91.44, which is below the consensus price target of $108.91, indicating that the stock may be undervalued and could appreciate as it approaches this target.
  • Boston Scientific Co. has a solid market capitalization of $135.25 billion, reflecting its strong position in the medical device industry and providing stability for investors.

Cons of Boston Scientific

  • Insider selling has been notable, with executives selling over 133,000 shares recently, which could signal a lack of confidence in the company's short-term performance.
  • The stock has a high price-to-earnings (P/E) ratio of 73.15, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite a strong market cap, the company has a relatively low insider ownership of only 0.50%, which may suggest a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$136.60 billion
P/E Ratio
73.88
Consensus Rating
Buy
Consensus Price Target
$108.91 (+17.9% Upside)
Volume
11.63 million shares
Average Volume
6.34 million shares
Today's Range
$91.01
$95.57
50-Day Range
$89.78
$106.20
52-Week Range
$66.80
$107.17
Dividend Yield
N/A
Stryker stock logo

14. Stryker NYSE:SYK

$347.04 -15.93 (-4.39%)
Closing price 03:59 PM Eastern
Extended Trading
$356.25 +9.21 (+2.65%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The company has a solid dividend yield of 0.97%, providing a steady income stream for investors. This yield is calculated based on the annualized dividend of $3.36 per share, which is attractive for income-focused investors.
  • Stryker Co. has a relatively low dividend payout ratio of 43.30%, indicating that it retains a significant portion of its earnings for reinvestment and growth, which can lead to long-term capital appreciation.
  • Recent insider trading activity shows confidence in the company, with Director Ronda E. Stryker selling a substantial number of shares but still retaining a significant ownership stake, valued at approximately $1.43 billion. This suggests that insiders believe in the company's future potential.

Cons of Stryker

  • Insider sales, such as the recent transaction by Director Allan C. Golston, where he sold 2,458 shares, may raise concerns about the company's short-term outlook, as it could indicate a lack of confidence in immediate performance.
  • The medical technology sector can be highly competitive and subject to regulatory changes, which may impact Stryker Co.'s market position and profitability.
  • With corporate insiders owning only 5.50% of the company's stock, there may be less alignment between management and shareholder interests, potentially leading to decisions that do not prioritize shareholder value.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$132.46 billion
P/E Ratio
44.72
Consensus Rating
Moderate Buy
Consensus Price Target
$421.90 (+21.6% Upside)
Volume
2.67 million shares
Average Volume
1.35 million shares
Today's Range
$337.45
$359.46
50-Day Range
$336.96
$399.01
52-Week Range
$314.93
$406.19
Dividend Yield
0.91%
Danaher stock logo

15. Danaher NYSE:DHR

$180.64 -11.25 (-5.86%)
Closing price 03:59 PM Eastern
Extended Trading
$183.48 +2.84 (+1.57%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. recently reported earnings per share (EPS) of $2.14, meeting analysts' expectations, which indicates strong financial performance and stability.
  • The company has increased its quarterly dividend to $0.32 per share, up from $0.27, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend of $1.28, providing a yield of approximately 0.74%.
  • Danaher Co. has a solid return on equity of 10.82%, suggesting effective management and profitability relative to shareholder equity.

Cons of Danaher

  • The stock has a relatively high P/E ratio of 34.22, which may suggest that it is overvalued compared to its earnings, potentially limiting future price growth.
  • Danaher Co. has a beta of 0.86, indicating lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • Insider ownership is at 11.10%, which, while not low, may indicate less alignment between management and shareholder interests compared to companies with higher insider ownership.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$129.11 billion
P/E Ratio
34.21
Consensus Rating
Moderate Buy
Consensus Price Target
$276.57 (+53.1% Upside)
Volume
6.29 million shares
Average Volume
3.31 million shares
Today's Range
$175.51
$192.45
50-Day Range
$173.85
$215.05
52-Week Range
$171.00
$281.70
Dividend Yield
0.65%
Remove Ads
Pfizer stock logo

16. Pfizer NYSE:PFE

$21.57 -0.92 (-4.10%)
Closing price 03:59 PM Eastern
Extended Trading
$21.60 +0.04 (+0.17%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. recently reported a quarterly earnings per share (EPS) of $0.63, exceeding analysts' expectations of $0.48, indicating strong financial performance and potential for growth.
  • The company has shown a year-over-year revenue increase of 24.7%, suggesting robust demand for its products and effective business strategies.
  • Pfizer Inc. has a market capitalization of approximately $127.61 billion, reflecting its significant size and stability in the biopharmaceutical sector.

Cons of Pfizer

  • Insider ownership is only 0.06%, which may indicate a lack of confidence from those closest to the company regarding its future prospects.
  • The stock has experienced volatility, with a 12-month low of $20.77, suggesting potential risks for investors concerned about price fluctuations.
  • Recent stock performance shows a decline of 3.9%, which could signal underlying issues or market sentiment that investors should consider.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$127.55 billion
P/E Ratio
15.30
Consensus Rating
Moderate Buy
Consensus Price Target
$31.07 (+44.1% Upside)
Volume
72.42 million shares
Average Volume
40.15 million shares
Today's Range
$21.09
$22.27
50-Day Range
$21.57
$26.76
52-Week Range
$20.92
$31.54
Dividend Yield
7.88%
Gilead Sciences stock logo

17. Gilead Sciences NASDAQ:GILD

$101.40 -3.85 (-3.66%)
Closing price 04:00 PM Eastern
Extended Trading
$100.72 -0.68 (-0.67%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Recent upgrades from multiple analysts, including a boost from Oppenheimer to a target price of $132.00, indicate strong market confidence in Gilead Sciences, Inc.'s growth potential.
  • The stock currently has a consensus rating of "Moderate Buy" from analysts, suggesting that the majority see potential for price appreciation.
  • Gilead Sciences, Inc. has a robust pipeline of biopharmaceutical products addressing unmet medical needs, which can lead to significant revenue growth.

Cons of Gilead Sciences

  • The high payout ratio of 854.05% raises concerns about sustainability, as it suggests that the company is distributing more in dividends than it earns, which could lead to financial strain.
  • Despite positive analyst ratings, the stock has faced volatility, which may deter risk-averse investors looking for stable investments.
  • With eleven analysts rating the stock as a hold, there is a significant portion of the market that is cautious about its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$126.26 billion
P/E Ratio
274.05
Consensus Rating
Moderate Buy
Consensus Price Target
$105.12 (+3.7% Upside)
Volume
14.19 million shares
Average Volume
7.48 million shares
Today's Range
$99.25
$105.00
50-Day Range
$95.48
$117.41
52-Week Range
$62.07
$119.96
Dividend Yield
2.81%
Sanofi stock logo

18. Sanofi NASDAQ:SNY

$49.66 -1.55 (-3.03%)
Closing price 04:00 PM Eastern
Extended Trading
$49.70 +0.04 (+0.08%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has recently received a "strong-buy" rating from Sanford C. Bernstein, indicating strong confidence from analysts in the company's future performance.
  • The stock is currently trading at $54.62, which is near its 1-year high of $60.12, suggesting potential for growth as it approaches previous highs.
  • Institutional interest is growing, with several hedge funds, including Congress Wealth Management LLC and Rahlfs Capital LLC, recently acquiring significant stakes in Sanofi, reflecting confidence in the company's prospects.

Cons of Sanofi

  • Despite recent positive ratings, the stock has experienced fluctuations, including a recent drop to $50.76, which may indicate volatility and uncertainty in the market.
  • Analysts have issued mixed ratings, with some lowering their expectations, such as StockNews.com reducing their rating from "buy" to "hold," which could signal caution for potential investors.
  • Sanofi's beta of 0.58 suggests lower volatility compared to the market, but it also indicates that the stock may not perform as strongly during market upswings, potentially limiting growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$125.45 billion
P/E Ratio
19.94
Consensus Rating
Buy
Consensus Price Target
$62.50 (+25.9% Upside)
Volume
2.66 million shares
Average Volume
2.32 million shares
Today's Range
$48.72
$50.21
50-Day Range
$49.66
$59.42
52-Week Range
$45.22
$60.12
Dividend Yield
2.91%
Vertex Pharmaceuticals stock logo

19. Vertex Pharmaceuticals NASDAQ:VRTX

$475.49 -6.81 (-1.41%)
Closing price 04:00 PM Eastern
Extended Trading
$473.10 -2.39 (-0.50%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals has a strong market capitalization of $121.30 billion, indicating a robust financial position and potential for growth.
  • The stock is currently trading at $472.37, which is near its twelve-month high of $519.88, suggesting strong investor interest and confidence in the company's future performance.
  • Recent analyst ratings show a consensus of "Moderate Buy," with ten analysts recommending a hold and sixteen recommending a buy, indicating positive sentiment among market experts.

Cons of Vertex Pharmaceuticals

  • The company reported earnings per share of $3.54, which missed analysts' expectations of $3.99, indicating potential challenges in meeting financial targets.
  • Vertex Pharmaceuticals has a negative return on equity of 2.02%, suggesting that the company is not currently generating profit relative to shareholder equity, which could be a red flag for investors.
  • The stock has a high P/E ratio of -214.71, indicating that the company may not be generating profits at the moment, which can deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$122.10 billion
P/E Ratio
-216.13
Consensus Rating
Moderate Buy
Consensus Price Target
$509.17 (+7.1% Upside)
Volume
2.25 million shares
Average Volume
1.32 million shares
Today's Range
$455.69
$480.00
50-Day Range
$453.20
$513.76
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Medtronic stock logo

20. Medtronic NYSE:MDT

$82.53 -2.75 (-3.22%)
Closing price 03:59 PM Eastern
Extended Trading
$84.00 +1.47 (+1.78%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc recently reported a quarterly earnings per share (EPS) of $1.39, exceeding analysts' expectations of $1.36, indicating strong financial performance and effective management.
  • The company has a solid market capitalization of $106.28 billion, reflecting its stability and potential for growth in the medical technology sector.
  • Medtronic plc has announced a quarterly dividend of $0.70, which translates to an annualized dividend yield of 3.38%. This can provide a steady income stream for investors.

Cons of Medtronic

  • The stock has recently experienced a decline of 5.7%, which may indicate volatility and uncertainty in the market.
  • Medtronic plc has a relatively high payout ratio of 85.11%, which could limit its ability to reinvest in growth opportunities and may raise concerns about sustainability of dividends.
  • Despite beating EPS estimates, the company's revenue of $8.29 billion fell short of the consensus estimate of $8.33 billion, suggesting potential challenges in revenue growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$105.85 billion
P/E Ratio
25.09
Consensus Rating
Hold
Consensus Price Target
$96.07 (+16.4% Upside)
Volume
7.98 million shares
Average Volume
6.67 million shares
Today's Range
$80.99
$85.30
50-Day Range
$81.64
$94.58
52-Week Range
$75.96
$96.25
Dividend Yield
3.19%
Remove Ads
Bristol-Myers Squibb stock logo

21. Bristol-Myers Squibb NYSE:BMY

$50.45 -3.29 (-6.12%)
Closing price 03:59 PM Eastern
Extended Trading
$50.30 -0.16 (-0.31%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

  • The company reported earnings per share (EPS) of $1.67, exceeding the consensus estimate of $1.47, indicating strong financial performance and effective management.
  • Bristol-Myers Squibb has a positive return on equity of 13.93%, suggesting that the company is efficient in generating profits from its equity investments.
  • The current stock price is $58.52, which is above the 200-day moving average of $56.72, indicating a potential upward trend in stock performance.

Cons of Bristol-Myers Squibb

  • The company has a negative net margin of 18.53%, indicating that it is currently spending more than it earns, which could raise concerns about profitability.
  • The payout ratio is -56.11%, suggesting that the company is paying out more in dividends than it is earning, which may not be sustainable in the long term.
  • Recent market volatility could impact the stock price, making it a riskier investment in the short term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$102.66 billion
P/E Ratio
-11.41
Consensus Rating
Hold
Consensus Price Target
$57.67 (+14.3% Upside)
Volume
23.97 million shares
Average Volume
12.92 million shares
Today's Range
$48.82
$53.42
50-Day Range
$50.45
$63.00
52-Week Range
$39.35
$63.33
Dividend Yield
4.29%
Elevance Health stock logo

22. Elevance Health NYSE:ELV

$436.08 +0.40 (+0.09%)
Closing price 03:59 PM Eastern
Extended Trading
$435.50 -0.58 (-0.13%)
As of 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$98.72 billion
P/E Ratio
17.03
Consensus Rating
Moderate Buy
Consensus Price Target
$519.71 (+19.2% Upside)
Volume
1.62 million shares
Average Volume
1.44 million shares
Today's Range
$428.29
$444.37
50-Day Range
$382.46
$452.70
52-Week Range
$362.21
$567.26
Dividend Yield
1.51%
The Cigna Group stock logo

23. The Cigna Group NYSE:CI

$327.31 +7.32 (+2.29%)
Closing price 03:59 PM Eastern
Extended Trading
$330.54 +3.22 (+0.98%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about The Cigna Group

Pros of The Cigna Group

  • The Cigna Group has a strong market capitalization of $88.13 billion, indicating a robust financial position and potential for growth.
  • Recent analyst ratings show a consensus "Buy" rating, with a target price averaging $373.25, suggesting that there is optimism about the stock's future performance.
  • The current stock price is $322.02, which is below the average target price set by analysts, presenting a potential buying opportunity for investors.

Cons of The Cigna Group

  • The stock has recently experienced a decline of 4.9%, which may indicate volatility and potential challenges in the market.
  • The company missed analysts' EPS estimates by $1.20, which could raise concerns about its ability to meet future financial expectations.
  • Insider selling has occurred, with the CEO selling 26,527 shares, which might signal a lack of confidence in the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$89.58 billion
P/E Ratio
26.74
Consensus Rating
Buy
Consensus Price Target
$374.44 (+14.4% Upside)
Volume
2.02 million shares
Average Volume
1.69 million shares
Today's Range
$318.07
$331.57
50-Day Range
$286.67
$338.76
52-Week Range
$262.03
$370.83
Dividend Yield
1.78%
CVS Health stock logo

24. CVS Health NYSE:CVS

$68.86 -1.32 (-1.89%)
Closing price 03:59 PM Eastern
Extended Trading
$68.97 +0.11 (+0.16%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. has a strong growth forecast, with several analysts recently raising their price targets, indicating confidence in the company's future performance. For instance, Truist Financial increased their price objective from $60.00 to $76.00, reflecting a bullish outlook.
  • The company has a solid dividend yield of 4.19%, with a recent quarterly dividend of $0.665 per share. This can provide a steady income stream for investors, especially those looking for income-generating investments.
  • CVS Health Co. reported earnings per share of $1.19, significantly exceeding analysts' expectations of $0.89. This strong performance can enhance investor confidence and potentially lead to stock price appreciation.

Cons of CVS Health

  • The company has a relatively high debt-to-equity ratio of 0.80, which may indicate higher financial risk. This could affect its ability to invest in growth opportunities or weather economic downturns.
  • CVS Health Co. has a net margin of only 1.24%, suggesting that the company may face challenges in converting revenue into profit, which could limit overall profitability and shareholder returns.
  • Despite recent upgrades from analysts, four analysts still rate the stock as a hold, indicating some uncertainty about its short-term performance and potential volatility in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.48 billion
P/E Ratio
18.81
Consensus Rating
Moderate Buy
Consensus Price Target
$71.00 (+3.1% Upside)
Volume
14.99 million shares
Average Volume
11.74 million shares
Today's Range
$68.34
$70.89
50-Day Range
$53.95
$70.40
52-Week Range
$43.56
$71.66
Dividend Yield
3.93%
McKesson stock logo

25. McKesson NYSE:MCK

$678.08 +6.32 (+0.94%)
Closing price 03:59 PM Eastern
Extended Trading
$733.64 +55.56 (+8.19%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • Recent analyst upgrades have increased price targets significantly, with Morgan Stanley raising their target to $745.00, indicating strong confidence in the company's future performance.
  • McKesson Co. has a consensus rating of "Moderate Buy" from analysts, suggesting that the majority believe the stock is a good investment opportunity.
  • The current stock price is $682.41, which is near its 52-week high of $728.32, reflecting strong market performance and investor interest.

Cons of McKesson

  • Insider selling has been notable, with CEO Brian S. Tyler selling 8,961 shares recently, which may raise concerns about the company's future prospects from those closest to it.
  • Despite positive ratings, Citigroup recently lowered their price target from $713.00 to $677.00, indicating some analysts may have reservations about the stock's short-term performance.
  • The stock has experienced fluctuations, with a recent drop of 4.8%, which could signal potential instability in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$84.98 billion
P/E Ratio
31.05
Consensus Rating
Moderate Buy
Consensus Price Target
$661.00 (-2.5% Downside)
Volume
988,862 shares
Average Volume
878,078 shares
Today's Range
$669.21
$691.77
50-Day Range
$593.82
$716.71
52-Week Range
$464.42
$744.74
Dividend Yield
0.42%
Remove Ads
HCA Healthcare stock logo

26. HCA Healthcare NYSE:HCA

$335.34 -3.19 (-0.94%)
Closing price 03:59 PM Eastern
Extended Trading
$338.50 +3.15 (+0.94%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • HCA Healthcare, Inc. reported a strong earnings per share (EPS) of $6.22 for the latest quarter, exceeding analysts' expectations of $6.03. This indicates robust financial performance and potential for continued growth.
  • The company has a high return on equity (ROE) of 586.47%, suggesting that it is highly effective at generating profits from its equity investments, which can be attractive to investors looking for efficient management.
  • HCA Healthcare, Inc. recently increased its quarterly dividend to $0.72, up from $0.66, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend of $2.88, providing a yield of 0.87%.

Cons of HCA Healthcare

  • The company has a relatively high debt-to-equity ratio of 69.07, which may indicate that it is heavily reliant on debt financing. This could pose risks, especially in a rising interest rate environment.
  • HCA Healthcare, Inc. has a quick ratio of 0.97, which is below 1.0, suggesting that it may struggle to meet its short-term liabilities without selling inventory or obtaining additional financing.
  • Recent insider selling, including a significant transaction by a senior vice president who sold over 9,500 shares, may raise concerns about the company's future prospects and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$82.56 billion
P/E Ratio
15.26
Consensus Rating
Moderate Buy
Consensus Price Target
$385.67 (+15.0% Upside)
Volume
2.13 million shares
Average Volume
1.39 million shares
Today's Range
$324.40
$342.17
50-Day Range
$305.79
$349.03
52-Week Range
$289.98
$417.14
Dividend Yield
0.82%
GSK stock logo

27. GSK NYSE:GSK

$33.65 -0.84 (-2.42%)
Closing price 03:59 PM Eastern
Extended Trading
$33.48 -0.16 (-0.48%)
As of 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc's stock is currently trading at $38.74, showing a recent increase of 0.6%, which may indicate positive market sentiment and potential for further growth.
  • Recent analyst upgrades, including a shift from a "buy" to a "strong-buy" rating by StockNews.com, suggest growing confidence in GSK plc's future performance.
  • The company has a solid market capitalization of $80.19 billion, indicating a strong position in the pharmaceutical industry, which can provide stability for investors.

Cons of GSK

  • The stock has a relatively high P/E ratio of 24.37, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • GSK plc has a beta of 0.58, suggesting lower volatility compared to the market, which may limit potential high returns for aggressive investors.
  • Despite recent upgrades, seven analysts have rated the stock with a hold rating, indicating uncertainty about its short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$69.64 billion
P/E Ratio
21.16
Consensus Rating
Moderate Buy
Consensus Price Target
$43.25 (+28.5% Upside)
Volume
8.48 million shares
Average Volume
4.61 million shares
Today's Range
$32.73
$34.26
50-Day Range
$33.65
$40.41
52-Week Range
$31.72
$45.93
Dividend Yield
4.03%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$146.90 -6.65 (-4.33%)
Closing price 03:59 PM Eastern
Extended Trading
$146.96 +0.06 (+0.04%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • Zoetis Inc. has demonstrated strong financial performance, reporting a net margin of 26.86% and a return on equity of 53.82%, indicating efficient management and profitability.
  • The company recently reported earnings per share (EPS) of $1.40, surpassing the consensus estimate of $1.37, which reflects its ability to generate higher-than-expected profits.
  • With a current stock price of $148.09, Zoetis Inc. is trading significantly below its 52-week high of $200.33, suggesting potential for price appreciation as the market stabilizes.

Cons of Zoetis

  • The stock has experienced volatility, recently trading down $3.65, which may indicate market uncertainty and potential risks for investors.
  • Despite strong earnings, the company's P/E ratio of 27.02 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Zoetis Inc. has a debt-to-equity ratio of 1.09, indicating a relatively high level of debt compared to equity, which could pose risks in times of economic downturns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$65.78 billion
P/E Ratio
26.86
Consensus Rating
Buy
Consensus Price Target
$215.90 (+47.0% Upside)
Volume
3.53 million shares
Average Volume
2.62 million shares
Today's Range
$142.04
$152.64
50-Day Range
$144.09
$175.65
52-Week Range
$139.70
$200.33
Dividend Yield
1.32%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$546.39 -30.33 (-5.26%)
Closing price 04:00 PM Eastern
Extended Trading
$537.50 -8.89 (-1.63%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • Regeneron Pharmaceuticals, Inc. reported a strong earnings per share (EPS) of $12.07 for the latest quarter, exceeding analysts' expectations of $11.21, indicating robust financial performance.
  • The company has a market capitalization of $62.69 billion, reflecting its significant size and stability in the biopharmaceutical sector.
  • With a net margin of 31.07%, Regeneron Pharmaceuticals, Inc. demonstrates effective cost management and profitability, which can lead to higher returns for investors.

Cons of Regeneron Pharmaceuticals

  • Analysts have recently downgraded price targets for the stock, with some reducing their expectations significantly, which may indicate a lack of confidence in future growth.
  • The company has a relatively high price-to-earnings (P/E) ratio of 15.05, which could suggest that the stock is overvalued compared to its earnings.
  • Regeneron Pharmaceuticals, Inc. has a beta of 0.44, indicating lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$59.73 billion
P/E Ratio
14.27
Consensus Rating
Moderate Buy
Consensus Price Target
$966.88 (+77.0% Upside)
Volume
1.35 million shares
Average Volume
705,340 shares
Today's Range
$529.72
$571.99
50-Day Range
$546.39
$744.83
52-Week Range
$525.99
$1,211.20
Dividend Yield
0.14%
Becton, Dickinson and Company stock logo

30. Becton, Dickinson and Company NYSE:BDX

$199.14 -10.21 (-4.87%)
Closing price 03:59 PM Eastern
Extended Trading
$199.58 +0.44 (+0.22%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • Becton, Dickinson and Company has received multiple upgrades from analysts, with a recent upgrade to a "buy" rating, indicating strong confidence in the company's future performance.
  • The average target price for Becton, Dickinson and Company is currently $278.29, suggesting potential for price appreciation from its current stock price of approximately $224.91.
  • Eight analysts have rated the stock with a buy rating, reflecting a consensus among experts that the stock is a favorable investment opportunity.

Cons of Becton, Dickinson and Company

  • Insider sales have occurred recently, with executives selling a total of 4,984 shares valued at over $1 million, which could raise concerns about the company's short-term outlook.
  • The stock has seen a decrease in ownership by insiders, which may suggest a lack of confidence among company executives regarding future performance.
  • Despite the positive analyst ratings, the stock's current price is significantly lower than the average target price, which could indicate potential volatility or market skepticism.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$57.18 billion
P/E Ratio
33.08
Consensus Rating
Buy
Consensus Price Target
$275.71 (+38.4% Upside)
Volume
2.93 million shares
Average Volume
1.68 million shares
Today's Range
$194.14
$207.26
50-Day Range
$199.15
$245.07
52-Week Range
$193.03
$251.99
Dividend Yield
1.88%
Remove Ads
Cencora stock logo

31. Cencora NYSE:COR

$279.04 +5.15 (+1.88%)
Closing price 03:59 PM Eastern
Extended Trading
$280.41 +1.37 (+0.49%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The stock has recently been rated as a "buy" by StockNews.com, indicating positive sentiment from analysts regarding its future performance.
  • JPMorgan Chase & Co. has increased their price target for Cencora, Inc. from $289.00 to $301.00, suggesting confidence in the company's growth potential.
  • As of the latest trading session, the stock price is $279.29, which reflects a strong market position and investor interest.

Cons of Cencora

  • The company has a high debt-to-equity ratio of 16.40, which suggests that it relies heavily on debt financing, potentially increasing financial risk.
  • Recent insider sales amount to 30,675 shares worth $8,034,778, which could signal a lack of confidence among insiders about the stock's future performance.
  • The stock has experienced significant fluctuations, with a 12-month low of $214.77 and a high of $296.65, indicating volatility that may concern risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$53.11 billion
P/E Ratio
39.69
Consensus Rating
Moderate Buy
Consensus Price Target
$280.20 (+0.4% Upside)
Volume
2.18 million shares
Average Volume
1.50 million shares
Today's Range
$272.70
$282.28
50-Day Range
$241.37
$289.41
52-Week Range
$214.77
$296.65
Dividend Yield
0.80%
Alcon stock logo

32. Alcon NYSE:ALC

$87.10 -2.89 (-3.22%)
Closing price 03:59 PM Eastern
Extended Trading
$86.74 -0.35 (-0.40%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • Alcon Inc. has shown a strong fifty-two week performance of 26.72%, indicating a positive trend in its stock price over the past year, which can attract investors looking for growth.
  • The current stock price is $91.98, reflecting a solid valuation that may appeal to investors seeking to enter at a favorable point.
  • Institutional ownership stands at 72.64%, suggesting that a significant portion of the company is held by institutional investors, which can indicate confidence in the company's future prospects.

Cons of Alcon

  • There has been a month-to-month increase in shares shorted, rising from 3,430,000 to 3,160,000, which could indicate growing skepticism among some investors about the company's future performance.
  • The days to cover is 4.5, suggesting that it may take longer for short sellers to cover their positions, which could lead to increased volatility if the stock price moves against them.
  • Despite a positive performance, the month-to-month change in shares shorted shows a slight decrease of 7.87%, which may indicate a cautious sentiment among investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.39 billion
P/E Ratio
37.22
Consensus Rating
Moderate Buy
Consensus Price Target
$106.22 (+22.0% Upside)
Volume
1.90 million shares
Average Volume
1.02 million shares
Today's Range
$85.50
$88.18
50-Day Range
$82.86
$96.95
52-Week Range
$77.54
$101.10
Dividend Yield
0.28%
Takeda Pharmaceutical stock logo

33. Takeda Pharmaceutical NYSE:TAK

$13.86 -0.48 (-3.31%)
Closing price 03:59 PM Eastern
Extended Trading
$14.16 +0.29 (+2.09%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Recent investment activity indicates strong institutional interest, with Fisher Asset Management LLC purchasing shares valued at approximately $547,000, suggesting confidence in the company's future performance.
  • Takeda Pharmaceutical Company Limited reported an earnings per share (EPS) of $0.42, exceeding the consensus estimate of $0.34, which reflects better-than-expected profitability and may attract more investors.
  • The current stock price is $15.04, which is near its 52-week high of $15.22, indicating positive momentum and potential for further appreciation.

Cons of Takeda Pharmaceutical

  • Despite recent positive earnings, the company has a relatively high price-to-earnings (P/E) ratio of 37.59, which may indicate that the stock is overvalued compared to its earnings.
  • The stock has shown volatility, with a beta of 0.46, suggesting that it may not respond strongly to market movements, which could limit potential gains.
  • Takeda Pharmaceutical has a net margin of only 4.53%, which is relatively low and may raise concerns about its profitability and operational efficiency.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.12 billion
P/E Ratio
34.66
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
2.88 million shares
Average Volume
1.85 million shares
Today's Range
$13.60
$14.08
50-Day Range
$13.26
$15.20
52-Week Range
$12.58
$15.37
Dividend Yield
3.63%
Haleon stock logo

34. Haleon NYSE:HLN

$9.64 -0.01 (-0.05%)
Closing price 03:59 PM Eastern
Extended Trading
$9.45 -0.20 (-2.02%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • Haleon plc reported a revenue of $3.54 billion during the latest quarter, exceeding the consensus estimate of $3.38 billion, indicating strong financial performance and potential for growth.
  • The company has a return on equity of 14.76%, which suggests effective management in generating profits from shareholders' equity, a positive sign for investors.
  • Haleon plc recently increased its dividend to $0.1166 per share, up from $0.05, reflecting a commitment to returning value to shareholders. This increase represents a yield of 1.6%, which can be attractive for income-focused investors.

Cons of Haleon

  • Despite the positive revenue growth, the company has a relatively high P/E ratio of 30.28, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Recent analyst ratings show a consensus rating of "Hold," with several brokerages downgrading their ratings, which may suggest a lack of strong bullish sentiment in the market.
  • The stock has a beta of 0.25, indicating lower volatility compared to the market. While this can be seen as stability, it may also limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.57 billion
P/E Ratio
28.37
Consensus Rating
Hold
Consensus Price Target
$10.95 (+13.5% Upside)
Volume
20.52 million shares
Average Volume
6.94 million shares
Today's Range
$9.41
$9.71
50-Day Range
$9.28
$10.68
52-Week Range
$7.99
$10.80
Dividend Yield
1.14%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$68.26 -1.64 (-2.35%)
Closing price 03:59 PM Eastern
Extended Trading
$67.76 -0.50 (-0.73%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company reported a quarterly earnings per share (EPS) of $0.59, exceeding analysts' expectations of $0.55, indicating strong financial performance and effective management.
  • Edwards Lifesciences Co. has a high net margin of 72.93%, suggesting that it retains a significant portion of revenue as profit, which is attractive for investors looking for profitability.
  • With a return on equity of 19.40%, the company demonstrates efficient use of shareholders' equity to generate profits, which can lead to higher returns for investors.

Cons of Edwards Lifesciences

  • Insider selling has been notable, with company insiders selling 62,553 shares valued at $4,513,064 over the last three months, which may indicate a lack of confidence in the stock's short-term performance.
  • Wolfe Research recently downgraded the stock from a "hold" rating to a "strong sell," reflecting concerns about the company's future performance and potential risks.
  • The stock has experienced volatility, with a 12-month high of $95.25 and a low of $58.93, indicating that it may be subject to significant price fluctuations, which can be risky for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.13 billion
P/E Ratio
9.79
Consensus Rating
Hold
Consensus Price Target
$79.95 (+17.1% Upside)
Volume
5.18 million shares
Average Volume
4.90 million shares
Today's Range
$66.77
$69.35
50-Day Range
$67.04
$76.23
52-Week Range
$58.93
$95.25
Dividend Yield
N/A
Remove Ads
Humana stock logo

36. Humana NYSE:HUM

$290.82 +5.30 (+1.85%)
Closing price 03:59 PM Eastern
Extended Trading
$288.25 -2.57 (-0.89%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price of Humana Inc. is $253.37, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Humana Inc. has a strong market capitalization of $30.58 billion, indicating a solid position in the market and potential for growth.
  • The company reported a quarterly earnings per share (EPS) of ($2.16), which was better than the consensus estimate of ($2.26), suggesting operational efficiency and potential for profitability improvements.

Cons of Humana

  • Humana Inc. has experienced a stock decline of 4.6%, which may indicate underlying issues or market sentiment that could affect future performance.
  • The company has a relatively high price-to-earnings (P/E) ratio of 25.46, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • With a debt-to-equity ratio of 0.68, while manageable, it indicates that the company is somewhat reliant on debt financing, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.10 billion
P/E Ratio
29.23
Consensus Rating
Hold
Consensus Price Target
$284.25 (-2.3% Downside)
Volume
2.01 million shares
Average Volume
1.75 million shares
Today's Range
$279.45
$293.88
50-Day Range
$249.32
$295.68
52-Week Range
$213.31
$406.46
Dividend Yield
1.33%
Veeva Systems stock logo

37. Veeva Systems NYSE:VEEV

$210.78 -6.26 (-2.88%)
Closing price 03:59 PM Eastern
Extended Trading
$209.00 -1.78 (-0.85%)
As of 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • Veeva Systems Inc. has received multiple upgrades from analysts, with Citigroup raising its price target to $307.00, indicating strong confidence in the company's growth potential.
  • The stock currently has a consensus rating of "Moderate Buy" from analysts, suggesting that a majority believe the stock will perform well in the near future.
  • As of the latest trading session, Veeva Systems Inc. shares are priced at $213.59, which is significantly below its 12-month high of $258.93, presenting a potential buying opportunity for investors looking for value.

Cons of Veeva Systems

  • The stock has experienced a recent decline, trading down 3.6% in one session, which may raise concerns about short-term volatility and market sentiment.
  • Veeva Systems Inc. has a high price-to-earnings (P/E) ratio of 52.74, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite positive analyst ratings, two analysts have issued sell ratings, indicating that there are differing opinions on the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.29 billion
P/E Ratio
52.04
Consensus Rating
Moderate Buy
Consensus Price Target
$256.52 (+21.7% Upside)
Volume
1.98 million shares
Average Volume
1.06 million shares
Today's Range
$204.10
$216.02
50-Day Range
$209.34
$247.10
52-Week Range
$170.25
$258.93
Dividend Yield
N/A
argenx stock logo

38. argenx NASDAQ:ARGX

$546.22 -17.91 (-3.17%)
Closing price 04:00 PM Eastern
Extended Trading
$577.26 +31.04 (+5.68%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenx

Pros of argenx

  • The current stock price of argenx SE is $555.11, which reflects a significant market capitalization of $33.73 billion, indicating strong investor interest and potential for growth.
  • Recent quarterly earnings showed a positive earnings per share (EPS) of $1.58, surpassing analysts' expectations of $0.98, which suggests strong operational performance and profitability potential.
  • Institutional ownership is robust, with 60.32% of the stock held by hedge funds and other institutional investors, indicating confidence from large investors in the company's future prospects.

Cons of argenx

  • The company has a high P/E ratio of -630.81, indicating that it is currently not profitable, which may deter risk-averse investors.
  • Despite strong revenue growth, argenx SE reported a negative net margin of 2.11%, suggesting that the company is currently operating at a loss, which could raise concerns about its financial health.
  • The stock has experienced significant volatility, with a 12-month high of $678.21 and a low of $352.77, indicating potential risks associated with price fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.19 billion
P/E Ratio
-620.70
Consensus Rating
Moderate Buy
Consensus Price Target
$687.00 (+25.8% Upside)
Volume
428,230 shares
Average Volume
304,351 shares
Today's Range
$535.27
$564.79
50-Day Range
$546.22
$671.74
52-Week Range
$352.77
$678.21
Dividend Yield
N/A
Cardinal Health stock logo

39. Cardinal Health NYSE:CAH

$129.00 -1.45 (-1.11%)
Closing price 03:59 PM Eastern
Extended Trading
$126.74 -2.25 (-1.75%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Cardinal Health, Inc. recently reported earnings per share (EPS) of $1.93, exceeding analysts' expectations of $1.74, indicating strong financial performance and potential for growth.
  • The company has a market capitalization of approximately $33.14 billion, reflecting its significant size and stability in the healthcare sector.
  • With a price-to-earnings (P/E) ratio of 25.60, Cardinal Health, Inc. is positioned competitively within the industry, suggesting that investors are willing to pay a premium for its earnings potential.

Cons of Cardinal Health

  • The company has a negative return on equity of 59.57%, indicating that it is currently not generating profit from its equity, which could raise concerns about its financial health.
  • Despite a recent positive earnings report, the net margin of 0.59% suggests that the company is operating with very thin profit margins, which may limit its ability to reinvest in growth.
  • Analysts have mixed ratings on the stock, with four holding a "hold" rating, which may indicate uncertainty about its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.16 billion
P/E Ratio
24.07
Consensus Rating
Moderate Buy
Consensus Price Target
$140.14 (+8.6% Upside)
Volume
2.93 million shares
Average Volume
2.18 million shares
Today's Range
$124.73
$130.28
50-Day Range
$124.07
$138.82
52-Week Range
$93.17
$139.50
Dividend Yield
1.48%
Centene stock logo

40. Centene NYSE:CNC

$62.46 -0.18 (-0.28%)
Closing price 03:59 PM Eastern
Extended Trading
$62.22 -0.23 (-0.38%)
As of 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • Centene Co. recently reported earnings per share (EPS) of $0.80, significantly exceeding analysts' expectations of $0.49, indicating strong financial performance and effective management.
  • The company has a market capitalization of $30.82 billion, which reflects its substantial size and stability in the healthcare sector, making it a potentially safer investment.
  • With a current stock price of $62.13, Centene Co. is trading below several analysts' price targets, suggesting potential for price appreciation as the market corrects.

Cons of Centene

  • Jefferies Financial Group recently downgraded Centene Co. from a "hold" to an "underperform" rating, which may signal concerns about the company's future performance.
  • One analyst has issued a sell rating on the stock, indicating that there are significant concerns about its valuation and future prospects.
  • The stock has a relatively low price-to-earnings (P/E) ratio of 9.96, which could suggest that the market has low expectations for future growth compared to its peers.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.98 billion
P/E Ratio
10.01
Consensus Rating
Moderate Buy
Consensus Price Target
$80.85 (+29.4% Upside)
Volume
5.91 million shares
Average Volume
4.69 million shares
Today's Range
$61.18
$63.56
50-Day Range
$55.94
$64.37
52-Week Range
$55.03
$80.59
Dividend Yield
N/A
Remove Ads
IDEXX Laboratories stock logo

41. IDEXX Laboratories NASDAQ:IDXX

$381.83 -15.27 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$381.80 -0.03 (-0.01%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The stock has received a "Moderate Buy" rating from analysts, indicating positive sentiment and potential for growth.
  • With a current stock price of $393.73, it is trading significantly below its 12-month high of $548.88, suggesting potential for price appreciation.
  • IDEXX Laboratories, Inc. has a strong market capitalization of $31.91 billion, reflecting its stability and established presence in the veterinary and testing markets.

Cons of IDEXX Laboratories

  • The stock has recently experienced a decline of 4.1%, which may indicate volatility and potential challenges in the market.
  • Insider ownership is relatively low at 2.11%, which could suggest a lack of alignment between management and shareholders.
  • The company's P/E ratio of 36.90 is relatively high, indicating that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.94 billion
P/E Ratio
35.79
Consensus Rating
Moderate Buy
Consensus Price Target
$533.75 (+39.8% Upside)
Volume
1.27 million shares
Average Volume
612,639 shares
Today's Range
$372.32
$397.08
50-Day Range
$361.04
$468.55
52-Week Range
$356.14
$548.88
Dividend Yield
N/A
ResMed stock logo

42. ResMed NYSE:RMD

$210.38 -6.06 (-2.80%)
Closing price 03:59 PM Eastern
Extended Trading
$211.28 +0.90 (+0.43%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • ResMed Inc. reported a strong quarterly earnings result with earnings per share of $2.43, exceeding analysts' expectations of $2.29. This indicates robust financial performance and effective management, which can lead to increased investor confidence.
  • The company has a solid net margin of 25.34%, suggesting that it retains a significant portion of revenue as profit after expenses. This high profitability can be attractive to investors looking for companies with strong financial health.
  • ResMed Inc. has a low debt-to-equity ratio of 0.13, indicating that it is not heavily reliant on debt to finance its operations. This financial stability can reduce risk for investors, especially in volatile markets.

Cons of ResMed

  • Despite strong earnings, the price-to-earnings ratio of 24.17 may indicate that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • The company has experienced insider selling, with executives selling a total of 41,004 shares worth over $9 million in recent months. This could signal a lack of confidence in the company's future performance from those who are most familiar with it.
  • ResMed Inc. operates in a competitive healthcare market, which can be subject to regulatory changes and technological advancements that may impact its market position and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.90 billion
P/E Ratio
24.84
Consensus Rating
Moderate Buy
Consensus Price Target
$249.73 (+18.7% Upside)
Volume
1.04 million shares
Average Volume
1.02 million shares
Today's Range
$206.97
$214.71
50-Day Range
$204.54
$242.19
52-Week Range
$172.19
$263.05
Dividend Yield
0.99%
Alnylam Pharmaceuticals stock logo

43. Alnylam Pharmaceuticals NASDAQ:ALNY

$226.28 -16.99 (-6.98%)
Closing price 04:00 PM Eastern
Extended Trading
$224.56 -1.72 (-0.76%)
As of 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The stock has a strong market capitalization of approximately $29.18 billion, indicating a solid position in the biopharmaceutical sector, which can attract institutional investors.
  • Recent analyst upgrades, including a target price increase from Stifel Nicolaus to $345.00, suggest a potential upside of 41.63% from the current stock price of $243.59, making it an attractive investment opportunity.
  • Alnylam Pharmaceuticals, Inc. has a high current ratio of 2.78, indicating strong liquidity and the ability to cover short-term liabilities, which is a positive sign for financial health.

Cons of Alnylam Pharmaceuticals

  • The stock has a negative price-to-earnings ratio of -103.37, indicating that the company is currently not profitable, which can be a red flag for potential investors.
  • Recent insider selling, including significant transactions by the CFO and EVP, may signal a lack of confidence in the company's short-term prospects, which could concern investors.
  • The stock has experienced volatility, with a 12-month high of $304.39 and a low of $141.98, indicating potential risks associated with price fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.44 billion
P/E Ratio
-104.28
Consensus Rating
Moderate Buy
Consensus Price Target
$316.25 (+39.8% Upside)
Volume
1.66 million shares
Average Volume
859,005 shares
Today's Range
$214.76
$235.33
50-Day Range
$224.32
$290.70
52-Week Range
$141.98
$304.39
Dividend Yield
N/A
GE HealthCare Technologies stock logo

44. GE HealthCare Technologies NASDAQ:GEHC

$62.28 -2.70 (-4.16%)
Closing price 04:00 PM Eastern
Extended Trading
$61.90 -0.38 (-0.61%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The stock has received multiple upgrades from analysts, with Citigroup raising its price target to $110.00, indicating strong confidence in the company's growth potential.
  • GE HealthCare Technologies Inc. recently reported an earnings per share (EPS) of $1.45, surpassing analysts' expectations, which reflects strong financial performance and profitability.
  • The company has a solid market capitalization of approximately $27.67 billion, suggesting it is a well-established player in the healthcare technology sector.

Cons of GE HealthCare Technologies

  • The stock has experienced significant volatility, with a recent drop of $11.49, which may raise concerns about its stability in the market.
  • Despite positive earnings, the company reported revenue of $5.32 billion, slightly below the consensus estimate, which could indicate challenges in meeting growth expectations.
  • The price-to-earnings (P/E) ratio is currently at 13.97, which, while not excessively high, may suggest that the stock is fairly valued and could limit upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.48 billion
P/E Ratio
14.38
Consensus Rating
Moderate Buy
Consensus Price Target
$97.73 (+56.9% Upside)
Volume
7.58 million shares
Average Volume
3.11 million shares
Today's Range
$59.70
$64.20
50-Day Range
$58.75
$93.48
52-Week Range
$57.65
$94.80
Dividend Yield
0.19%
Agilent Technologies stock logo

45. Agilent Technologies NYSE:A

$99.77 -7.28 (-6.80%)
Closing price 03:59 PM Eastern
Extended Trading
$103.70 +3.93 (+3.94%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. reported a strong quarterly earnings performance with earnings per share of $1.31, exceeding analysts' expectations, which indicates robust financial health and effective management.
  • The company has a solid return on equity of 25.56%, suggesting that it is efficient in generating profits from its equity investments, which is attractive for investors looking for high returns.
  • With a current ratio of 2.20, Agilent Technologies, Inc. demonstrates strong liquidity, meaning it has more than enough short-term assets to cover its short-term liabilities, reducing financial risk.

Cons of Agilent Technologies

  • Insider selling has been observed, with executives selling shares totaling 5,638 shares valued at $731,229 in the last three months, which may signal a lack of confidence in the company's short-term prospects.
  • The company's debt-to-equity ratio of 0.56, while manageable, indicates that it is somewhat reliant on debt financing, which could pose risks if interest rates rise or if the company faces financial challenges.
  • Despite strong earnings, the net margin of 19.27% suggests that there may be pressures on profitability, which could affect future earnings growth and investor returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.44 billion
P/E Ratio
22.93
Consensus Rating
Hold
Consensus Price Target
$146.25 (+46.6% Upside)
Volume
4.98 million shares
Average Volume
1.85 million shares
Today's Range
$96.81
$105.28
50-Day Range
$98.97
$147.92
52-Week Range
$96.43
$155.35
Dividend Yield
1.00%
Remove Ads
DexCom stock logo

46. DexCom NASDAQ:DXCM

$67.30 +0.46 (+0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$67.08 -0.22 (-0.33%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • DexCom, Inc. has a strong market capitalization of approximately $24.02 billion, indicating a robust position in the medical device industry, which can attract more investors.
  • The company reported a return on equity of 30.14%, showcasing its ability to generate profit from shareholders' equity, which is a positive indicator of financial health.
  • With a recent stock price of $60.33, investors may find the current valuation attractive compared to its 52-week high of $141.99, suggesting potential for price recovery.

Cons of DexCom

  • The stock has experienced significant volatility, with a beta of 1.50, indicating that it is more volatile than the market, which can pose risks for investors.
  • Recent earnings reports showed that the company missed analysts' consensus estimates by $0.05, which may raise concerns about its short-term performance and growth prospects.
  • Insider selling has been noted, with executives selling over 105,000 shares recently, which could signal a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.39 billion
P/E Ratio
47.06
Consensus Rating
Moderate Buy
Consensus Price Target
$99.00 (+47.1% Upside)
Volume
8.91 million shares
Average Volume
4.18 million shares
Today's Range
$66.46
$73.50
50-Day Range
$59.83
$90.75
52-Week Range
$57.52
$141.25
Dividend Yield
N/A
IQVIA stock logo

47. IQVIA NYSE:IQV

$142.96 -14.06 (-8.96%)
Closing price 03:59 PM Eastern
Extended Trading
$143.16 +0.20 (+0.14%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • Strong Return on Equity: IQVIA Holdings Inc. has a return on equity of 28.81%, indicating effective management and profitability relative to shareholder equity, which can attract investors looking for efficient companies.
  • Positive Earnings Forecast: Analysts expect IQVIA Holdings Inc. to post an earnings per share (EPS) of 10.84 for the current fiscal year, suggesting potential growth and profitability that could lead to higher stock prices.
  • Recent Analyst Upgrades: Several analysts have recently issued buy ratings and increased price targets for IQVIA Holdings Inc., with a consensus price target of $249.05, indicating confidence in the company's future performance.

Cons of IQVIA

  • Recent Earnings Miss: The company reported an EPS of $2.90, missing analysts' expectations of $3.11 by $0.21, which may raise concerns about its ability to meet future earnings targets.
  • Mixed Analyst Ratings: While there are many buy ratings, there are also several hold and neutral ratings, indicating a lack of consensus among analysts about the stock's potential, which could lead to volatility.
  • Net Margin Concerns: With a net margin of 8.91%, there may be concerns about profitability, especially in a competitive market where margins can be squeezed.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.21 billion
P/E Ratio
19.06
Consensus Rating
Moderate Buy
Consensus Price Target
$241.50 (+68.9% Upside)
Volume
3.28 million shares
Average Volume
1.37 million shares
Today's Range
$140.33
$152.96
50-Day Range
$142.96
$209.76
52-Week Range
$135.97
$252.88
Dividend Yield
N/A
BioNTech stock logo

48. BioNTech NASDAQ:BNTX

$93.12 -1.02 (-1.08%)
Closing price 04:00 PM Eastern
Extended Trading
$93.12 +0.00 (+0.01%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • Recent earnings per share (EPS) of $1.08 exceeded the consensus estimate of $0.38, indicating strong performance relative to expectations.
  • Analysts have a positive outlook, with an average price target of $143.73, suggesting potential for stock appreciation.
  • Institutional investors have shown increased interest, with significant stakes being added, indicating confidence in the company's future.

Cons of BioNTech

  • The company reported a negative return on equity of 2.35% and a negative net margin of 15.16%, indicating challenges in profitability.
  • Quarterly revenue of $1.19 billion fell short of analysts' expectations of $1.24 billion, reflecting potential operational issues.
  • Year-over-year revenue decreased by 19.5%, suggesting a decline in business performance compared to the previous year.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$22.35 billion
P/E Ratio
-44.34
Consensus Rating
Moderate Buy
Consensus Price Target
$143.44 (+54.0% Upside)
Volume
1.17 million shares
Average Volume
852,472 shares
Today's Range
$89.69
$94.29
50-Day Range
$86.65
$122.78
52-Week Range
$76.53
$131.49
Dividend Yield
N/A
Mettler-Toledo International stock logo

49. Mettler-Toledo International NYSE:MTD

$998.10 -63.56 (-5.99%)
Closing price 03:59 PM Eastern
Extended Trading
$996.85 -1.25 (-0.13%)
As of 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The company recently reported earnings per share (EPS) of $12.41, exceeding analysts' expectations of $11.76, indicating strong financial performance and potential for growth.
  • Mettler-Toledo International Inc. has a market capitalization of approximately $22.80 billion, reflecting its significant size and stability in the medical instruments sector.
  • The stock is currently trading at $1,094.01, which is below its 12-month high of $1,546.93, suggesting potential for price appreciation as it may recover towards its previous highs.

Cons of Mettler-Toledo International

  • The stock has experienced a significant decline, trading down $78.49 recently, which may indicate volatility and potential risks for investors.
  • Insider selling activity, such as Gerry Keller's sale of 600 shares, which resulted in a 99.01% decrease in their ownership, could signal a lack of confidence in the company's short-term performance.
  • The company reported a negative return on equity of 591.54%, which suggests inefficiencies in generating profit from shareholders' equity, raising concerns about financial management.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$22.13 billion
P/E Ratio
24.63
Consensus Rating
Hold
Consensus Price Target
$1,380.50 (+38.3% Upside)
Volume
381,702 shares
Average Volume
137,908 shares
Today's Range
$964.43
$1,033.66
50-Day Range
$969.01
$1,390.00
52-Week Range
$946.69
$1,546.93
Dividend Yield
N/A
STERIS stock logo

50. STERIS NYSE:STE

$217.01 -5.93 (-2.66%)
Closing price 03:59 PM Eastern
Extended Trading
$217.12 +0.10 (+0.05%)
As of 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. More about STERIS

Pros of STERIS

  • STERIS plc has a strong market capitalization of $20.94 billion, indicating a robust financial position and potential for growth.
  • The company reported a quarterly earnings per share (EPS) of $2.32, which, despite missing the consensus estimate slightly, reflects solid profitability in the medical equipment sector.
  • With a current stock price of $213.16, STERIS plc is positioned within a 12-month range of $197.82 to $248.24, suggesting potential for price appreciation.

Cons of STERIS

  • STERIS plc's P/E ratio stands at 45.26, which is relatively high, suggesting that the stock may be overvalued compared to its earnings, potentially limiting future price growth.
  • The company recently experienced a slight miss in earnings expectations, which could indicate challenges in meeting market forecasts and may affect investor confidence.
  • Despite a strong market position, the medical equipment sector can be highly competitive and subject to regulatory changes, which may impact STERIS plc's operations and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$21.90 billion
P/E Ratio
46.07
Consensus Rating
Moderate Buy
Consensus Price Target
$258.75 (+19.2% Upside)
Volume
701,018 shares
Average Volume
537,257 shares
Today's Range
$212.34
$221.76
50-Day Range
$208.26
$233.02
52-Week Range
$197.82
$248.24
Dividend Yield
1.09%
Remove Ads